6.1. tat1 tumours. treatment take account patient’s prognosis. order predict risk disease recurrence and/or progression, several prognostic models specified patient populations introduced. 6.1.1. scoring models using 1973 classification system 6.1.1.1. 2006 european organisation research treatment cancer (eortc) scoring model able predict short- long-term risks disease recurrence progression individual patients, eortc genito-urinary cancer group (gucg) published scoring system risk tables based 1973 classification 2006 . scoring system based 6 significant clinical pathological factors patients mainly treated intravesical chemotherapy: number tumours;tumour diameter;prior recurrence rate;t category;concurrent cis;who 1973 tumour grade. using 2006 eortc scoring model, individual probabilities recurrence progression 1 5 years may calculated (https://www.omnicalculator.com/health/eortc-bladder-cancer). 6.1.1.2. model patients ta g1/g2 (who 1973) tumours treated chemotherapy patients ta g1/g2 tumours receiving chemotherapy stratified 3 risk groups recurrence, taking account history recurrences, history intravesical treatment, tumour grade (who 1973), number tumours adjuvant chemotherapy . 6.1.1.3. club urologico español de tratamiento oncologico (cueto) scoring model bcg-treated patients model predicts risk recurrence progression, based 12 doses intravesical bcg 5 6 months period following turb, published cueto (spanish urological oncology group). based analysis 1,062 patients 4 cueto trials compared different intravesical bcg treatments. immediate post-operative instillation second turb performed patients. scoring system based evaluation seven prognostic factors: gender;age;prior recurrence status;number tumours;t category;associated cis;who 1973 tumour grade. using model, calculated risk recurrence lower obtained eortc tables. progression, probability lower high-risk patients (le: 2a). lower risks cueto tables may attributed use bcg study. prognostic value eortc scoring system confirmed data cueto patients treated bcg long-term follow-up another patient population . 6.1.1.4. 2016 eortc scoring model patients treated maintenance bcg 1,812 intermediate- high-risk patients without cis treated 1 3 years maintenance bcg, eortc found prior disease-recurrence rate number tumours important prognostic factors disease recurrence, stage 1973 grade disease progression disease- specific survival, age 1973 grade important prognostic factors os. t1 g3 patients poorly, 1- 5-year disease-progression rates 11.4% 19.8%, respectively. using data, eortc risk groups nomograms bcg-treated patients developed . 6.1.2. scoring model using 2004/2016 1973 classification systems 6.1.2.1. eau nmibc 2021 scoring model update risk disease progression create new prognostic factor risk groups using 1973 2004/2016 classification systems (without central pathology review), individual patient data 3,401 primary patients treated 1990 2018 used (see section 4.5). patients treated turb ± intravesical chemotherapy included, treated adjuvant intravesical bcg excluded bcg may reduce risk disease progression. multivariate analyses, tumour stage, 1973 grade, 2004/2022 grade, concomitant cis, number tumours, tumour size age independent predictors disease progression . available model 2004/2022 classification system included one parameters calculate individual patient’s risk group probability progression. 2004/2022 classification system main grading classification system used pathologists, guidelines panel recommends use 2021 eau nmibc scoring model risk groups definition (see section 6.3). 2021 eau nmibc scoring model determines risk tumour progression, recurrence; therefore models mentioned section 6.1.1 may used calculation individual’s risk disease recurrence. 6.1.3. prognostic factors prognostic factors described selected patient populations: t1 hg/g3 tumours, important prognostic factors female sex, cis prostatic urethra men treated induction course bcg, age, tumour size concurrent cis bcg-treated patients (62% induction course only) .attention must given patients t1 hg/g3 tumours bladder diverticulum absence muscle layer diverticular wall .in patients t1 tumours, finding residual t1 disease second turb unfavourable prognostic factor [212-214].in patients t1g2 tumours treated turb, recurrence 3 months important predictor progression .the prognostic value pathological factors discussed elsewhere (see section 4.6). research needed determine role molecular markers improving predictive accuracy currently available risk tables .